diabetes glp 1 GLP-1R and Practice Nursing - GLP-1 receptor
Description
12 Commonly, patients may experience gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (65)
Why Purity
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
The effect of GLP-1 receptor agonists on circulating inflammatory markers: systematic review and meta-analysis
The Food and Drug Administration approves several of these drugs specifically for chronic weight management because they work so well
